Global Autogenous Vaccines Market Size, Share, Trends and Forecast 2022-2030

Description

Autogenous vaccines, also called autologous vaccines, autovaccines, "self" or custom vaccines, are vaccines, which prepared by isolation and destruction of microorganisms in infected individuals and used to provide immunity to the same individual. Generally, indications of autogenous vaccines include resistance of pathogenic microorganisms to antibiotic treatment, ineffective therapy or immune response and lack of commercial vaccines.
Industry Insights

Due to the COVID-19 pandemic, the global Autogenous Vaccines market size is estimated to be worth US$ 433 million in 2021 and is forecast to a readjusted size of US$ 587.4 million by 2028 with a CAGR of 4.4% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Autogenous Vaccines market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Autogenous Vaccines landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

Global Autogenous Vaccines key players include Boehringer Ingelheim, Vaxxinova, Zoetis, Ceva Biovac, Phibro, etc. Global top five manufacturers hold a share over 50%. America is the largest market, with a share about 45%, followed by Europe and Asia Pacific, total have a share over 50 percent. In terms of product, Poultry is the largest segment, with a share over 50%. And in terms of application, the largest application is Large Farms, followed by Small Farms.

This report focuses on Autogenous Vaccines volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Autogenous Vaccines market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, South Africa and Australia, etc.

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Post-covid-19 Outlook

The readers in the section will understand how the Autogenous Vaccines market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Segmental Outlook

Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).

Segment by Obejection

Poultry

Fishes

Pigs & Cattle

Other

Segment by Application

Large Farms

Small Farms

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Scenario

In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Boehringer Ingelheim

Vaxxinova

Zoetis

Ceva Biovac

Phibro

Elanco

AniCon Labor GmbH

Cambridge Technologies

AVICARE plus

Genova Labs

Addison Biological Laboratory

ACE Laboratory Services

Deltamune

Dyntec

Hygieia Biological Laboratories

TABLE OF CONTENT

1 Autogenous Vaccines Market Overview
1.1 Product Overview and Scope of Autogenous Vaccines

1.2 Autogenous Vaccines Segment by Obejection

1.2.1 Global Autogenous Vaccines Sales Growth Rate Comparison by Obejection (2022-2028)

1.2.2 Poultry

1.2.3 Fishes

1.2.4 Pigs & Cattle

1.2.5 Other

1.3 Autogenous Vaccines Segment by Application

1.3.1 Global Autogenous Vaccines Sales Comparison by Application: (2022-2028)

1.3.2 Large Farms

1.3.3 Small Farms

1.4 Global Autogenous Vaccines Market Size Estimates and Forecasts

1.4.1 Global Autogenous Vaccines Revenue 2017-2028

1.4.2 Global Autogenous Vaccines Sales 2017-2028

1.4.3 Autogenous Vaccines Market Size by Region: 2017 Versus 2021 Versus 2028

2 Autogenous Vaccines Market Competition by Manufacturers

2.1 Global Autogenous Vaccines Sales Market Share by Manufacturers (2017-2022)

2.2 Global Autogenous Vaccines Revenue Market Share by Manufacturers (2017-2022)

2.3 Global Autogenous Vaccines Average Price by Manufacturers (2017-2022)

2.4 Manufacturers Autogenous Vaccines Manufacturing Sites, Area Served, Product Type

2.5 Autogenous Vaccines Market Competitive Situation and Trends

2.5.1 Autogenous Vaccines Market Concentration Rate

2.5.2 The Global Top 5 and Top 10 Largest Autogenous Vaccines Players Market Share by Revenue

2.5.3 Global Autogenous Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Autogenous Vaccines Retrospective Market Scenario by Region

3.1 Global Autogenous Vaccines Retrospective Market Scenario in Sales by Region: 2017-2022

3.2 Global Autogenous Vaccines Retrospective Market Scenario in Revenue by Region: 2017-2022

3.3 North America Autogenous Vaccines Market Facts & Figures by Country

3.3.1 North America Autogenous Vaccines Sales by Country

3.3.2 North America Autogenous Vaccines Revenue by Country

3.3.3 United States

3.3.4 Canada

3.4 Europe Autogenous Vaccines Market Facts & Figures by Country

3.4.1 Europe Autogenous Vaccines Sales by Country

3.4.2 Europe Autogenous Vaccines Revenue by Country

3.4.3 Germany

3.4.4 France

3.4.5 U.K.

3.4.6 Italy

3.4.7 Russia

3.5 Asia Pacific Autogenous Vaccines Market Facts & Figures by Region

3.5.1 Asia Pacific Autogenous Vaccines Sales by Region

3.5.2 Asia Pacific Autogenous Vaccines Revenue by Region

3.5.3 China

3.5.4 Japan

3.5.5 South Korea

3.5.6 India

3.5.7 Australia

3.5.8 China Taiwan

3.5.9 Indonesia

3.5.10 Thailand

3.5.11 Malaysia

3.6 Latin America Autogenous Vaccines Market Facts & Figures by Country

3.6.1 Latin America Autogenous Vaccines Sales by Country

3.6.2 Latin America Autogenous Vaccines Revenue by Country

3.6.3 Mexico

3.6.4 Brazil

3.6.5 Argentina

3.7 Middle East and Africa Autogenous Vaccines Market Facts & Figures by Country

3.7.1 Middle East and Africa Autogenous Vaccines Sales by Country

3.7.2 Middle East and Africa Autogenous Vaccines Revenue by Country

3.7.3 Turkey

3.7.4 Saudi Arabia

3.7.5 UAE

4 Global Autogenous Vaccines Historic Market Analysis by Obejection

4.1 Global Autogenous Vaccines Sales Market Share by Obejection (2017-2022)

4.2 Global Autogenous Vaccines Revenue Market Share by Obejection (2017-2022)

4.3 Global Autogenous Vaccines Price by Obejection (2017-2022)

5 Global Autogenous Vaccines Historic Market Analysis by Application

5.1 Global Autogenous Vaccines Sales Market Share by Application (2017-2022)

5.2 Global Autogenous Vaccines Revenue Market Share by Application (2017-2022)

5.3 Global Autogenous Vaccines Price by Application (2017-2022)

6 Key Companies Profiled

6.1 Boehringer Ingelheim

6.1.1 Boehringer Ingelheim Corporation Information

6.1.2 Boehringer Ingelheim Description and Business Overview

6.1.3 Boehringer Ingelheim Autogenous Vaccines Sales, Revenue and Gross Margin (2017-2022)

6.1.4 Boehringer Ingelheim Autogenous Vaccines Product Portfolio

6.1.5 Boehringer Ingelheim Recent Developments/Updates

6.2 Vaxxinova

6.2.1 Vaxxinova Corporation Information

6.2.2 Vaxxinova Description and Business Overview

6.2.3 Vaxxinova Autogenous Vaccines Sales, Revenue and Gross Margin (2017-2022)

6.2.4 Vaxxinova Autogenous Vaccines Product Portfolio

6.2.5 Vaxxinova Recent Developments/Updates

6.3 Zoetis

6.3.1 Zoetis Corporation Information

6.3.2 Zoetis Description and Business Overview

6.3.3 Zoetis Autogenous Vaccines Sales, Revenue and Gross Margin (2017-2022)

6.3.4 Zoetis Autogenous Vaccines Product Portfolio

6.3.5 Zoetis Recent Developments/Updates

6.4 Ceva Biovac

6.4.1 Ceva Biovac Corporation Information

6.4.2 Ceva Biovac Description and Business Overview

6.4.3 Ceva Biovac Autogenous Vaccines Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Ceva Biovac Autogenous Vaccines Product Portfolio

6.4.5 Ceva Biovac Recent Developments/Updates

6.5 Phibro

6.5.1 Phibro Corporation Information

6.5.2 Phibro Description and Business Overview

6.5.3 Phibro Autogenous Vaccines Sales, Revenue and Gross Margin (2017-2022)

6.5.4 Phibro Autogenous Vaccines Product Portfolio

6.5.5 Phibro Recent Developments/Updates

6.6 Elanco

6.6.1 Elanco Corporation Information

6.6.2 Elanco Description and Business Overview

6.6.3 Elanco Autogenous Vaccines Sales, Revenue and Gross Margin (2017-2022)

6.6.4 Elanco Autogenous Vaccines Product Portfolio

6.6.5 Elanco Recent Developments/Updates

6.7 AniCon Labor GmbH

6.6.1 AniCon Labor GmbH Corporation Information

6.6.2 AniCon Labor GmbH Description and Business Overview

6.6.3 AniCon Labor GmbH Autogenous Vaccines Sales, Revenue and Gross Margin (2017-2022)

6.4.4 AniCon Labor GmbH Autogenous Vaccines Product Portfolio

6.7.5 AniCon Labor GmbH Recent Developments/Updates

6.8 Cambridge Technologies

6.8.1 Cambridge Technologies Corporation Information

6.8.2 Cambridge Technologies Description and Business Overview

6.8.3 Cambridge Technologies Autogenous Vaccines Sales, Revenue and Gross Margin (2017-2022)

6.8.4 Cambridge Technologies Autogenous Vaccines Product Portfolio

6.8.5 Cambridge Technologies Recent Developments/Updates

6.9 AVICARE plus

6.9.1 AVICARE plus Corporation Information

6.9.2 AVICARE plus Description and Business Overview

6.9.3 AVICARE plus Autogenous Vaccines Sales, Revenue and Gross Margin (2017-2022)

6.9.4 AVICARE plus Autogenous Vaccines Product Portfolio

6.9.5 AVICARE plus Recent Developments/Updates

6.10 Genova Labs

6.10.1 Genova Labs Corporation Information

6.10.2 Genova Labs Description and Business Overview

6.10.3 Genova Labs Autogenous Vaccines Sales, Revenue and Gross Margin (2017-2022)

6.10.4 Genova Labs Autogenous Vaccines Product Portfolio

6.10.5 Genova Labs Recent Developments/Updates

6.11 Addison Biological Laboratory

6.11.1 Addison Biological Laboratory Corporation Information

6.11.2 Addison Biological Laboratory Autogenous Vaccines Description and Business Overview

6.11.3 Addison Biological Laboratory Autogenous Vaccines Sales, Revenue and Gross Margin (2017-2022)

6.11.4 Addison Biological Laboratory Autogenous Vaccines Product Portfolio

6.11.5 Addison Biological Laboratory Recent Developments/Updates

6.12 ACE Laboratory Services

6.12.1 ACE Laboratory Services Corporation Information

6.12.2 ACE Laboratory Services Autogenous Vaccines Description and Business Overview

6.12.3 ACE Laboratory Services Autogenous Vaccines Sales, Revenue and Gross Margin (2017-2022)

6.12.4 ACE Laboratory Services Autogenous Vaccines Product Portfolio

6.12.5 ACE Laboratory Services Recent Developments/Updates

6.13 Deltamune

6.13.1 Deltamune Corporation Information

6.13.2 Deltamune Autogenous Vaccines Description and Business Overview

6.13.3 Deltamune Autogenous Vaccines Sales, Revenue and Gross Margin (2017-2022)

6.13.4 Deltamune Autogenous Vaccines Product Portfolio

6.13.5 Deltamune Recent Developments/Updates

6.14 Dyntec

6.14.1 Dyntec Corporation Information

6.14.2 Dyntec Autogenous Vaccines Description and Business Overview

6.14.3 Dyntec Autogenous Vaccines Sales, Revenue and Gross Margin (2017-2022)

6.14.4 Dyntec Autogenous Vaccines Product Portfolio

6.14.5 Dyntec Recent Developments/Updates

6.15 Hygieia Biological Laboratories

6.15.1 Hygieia Biological Laboratories Corporation Information

6.15.2 Hygieia Biological Laboratories Autogenous Vaccines Description and Business Overview

6.15.3 Hygieia Biological Laboratories Autogenous Vaccines Sales, Revenue and Gross Margin (2017-2022)

6.15.4 Hygieia Biological Laboratories Autogenous Vaccines Product Portfolio

6.15.5 Hygieia Biological Laboratories Recent Developments/Updates

7 Autogenous Vaccines Manufacturing Cost Analysis

7.1 Autogenous Vaccines Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Key Suppliers of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.3 Manufacturing Process Analysis of Autogenous Vaccines

7.4 Autogenous Vaccines Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

8.1 Marketing Channel

8.2 Autogenous Vaccines Distributors List

8.3 Autogenous Vaccines Customers

9 Autogenous Vaccines Market Dynamics

9.1 Autogenous Vaccines Industry Trends

9.2 Autogenous Vaccines Market Drivers

9.3 Autogenous Vaccines Market Challenges

9.4 Autogenous Vaccines Market Restraints

10 Global Market Forecast

10.1 Autogenous Vaccines Market Estimates and Projections by Obejection

10.1.1 Global Forecasted Sales of Autogenous Vaccines by Obejection (2023-2028)

10.1.2 Global Forecasted Revenue of Autogenous Vaccines by Obejection (2023-2028)

10.2 Autogenous Vaccines Market Estimates and Projections by Application

10.2.1 Global Forecasted Sales of Autogenous Vaccines by Application (2023-2028)

10.2.2 Global Forecasted Revenue of Autogenous Vaccines by Application (2023-2028)

10.3 Autogenous Vaccines Market Estimates and Projections by Region

10.3.1 Global Forecasted Sales of Autogenous Vaccines by Region (2023-2028)

10.3.2 Global Forecasted Revenue of Autogenous Vaccines by Region (2023-2028)

11 Research Finding and Conclusion

12 Methodology and Data Source

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Author List

12.4 Disclaimer

Choose License Type

Checkout Inquiry Sample